RNA241115C27000
- 0.00
- 0.000.00%
Avidity Biosciences Newsroom
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $75
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation Of Biomarker Cohort In FORTITUDE Trial For Delpacibart Braxlosiran In People Living With Facioscapulohumeral Muscular Dystrophy
Express News | Avidity Biosciences: Enrollment in Del-Brax Biomarker Cohort Expected to Be Completed in 1H 2025
Express News | Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation of Biomarker Cohort in Fortitude™ Trial for Delpacibart Braxlosiran (Del-Brax/Aoc 1020) in People Living With Facioscapulohumeral Muscular Dystrophy
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Analyst Ratings
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $78
Avidity Biosciences Price Target Raised to $78 From $56 at TD Cowen
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
S&P 500 Futures Fall In Premarket Trading; AO Smith, Tesla Lag
Avidity Biosciences Insider Sold Shares Worth $1,349,259, According to a Recent SEC Filing
12 Health Care Stocks Moving In Monday's After-Market Session
Why Avidity Biosciences Zoomed to a 12% Gain This Week
Capricor Stock Rallies 20% on DMD Data Presentation Update